NewAmsterdam Pharma Company N.V. (NAMS) Presents at Citi’s Biopharma Back to School

Geoffrey Meacham
Managing Director

All right. Welcome to the second day of the Citi Back-to-school Biopharma Conference. This is the 20th annual. We took a little hiatus last year, but I’m happy that it’s back. I’m Geoff Meacham. My team is here as well. NewAmsterdam. Thanks, guys, for joining. It’s going to be a good dialogue here. So we have Michael Davidson, CEO; Ian Somaiya, CFO.

So I don’t know if you would want to kick it off with kind of like the 2-minute pitch. We have tons of questions. Congrats on all like the huge Phase III progress. I don’t know if you want to give a quick 2 minutes, and then we can get into questions or it’s up to you.

Michael Davidson
CEO, President & Executive Board Member

Sure. Thanks for being here, and I appreciate being included. So NewAmsterdam Pharma, we ended last year with our fantastic Phase III data, BROADWAY, showing great efficacy on LDL lowering and safety, no different from placebo, but we got very excited about the whole MACE benefit of 21%, 4-point MACE reduction. We raised the financing off of that, entered the year in a very strong position cash-wise. And this year, a lot of other great achievements. We published the BROADWAY paper in New England Journal of Medicine. The fixed-dose combination study we published called TANDEM was published in Lancet. We now just published in JACC this past week and presented at the European Society of Cardiology, the pooled MACE data from both our 2 Phase III, BROOKLYN and BROADWAY, showing the pooled MACE data looking even more than 21% relative risk reduction for the